Human HLA-A*03:01&B2M&GP100 (ALLAVGATK) Tetramer Protein
Catalog No: GP100-HP004
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
Product overview
Recombinant Human HLA-A*03:01&B2M&gp100 (ALLAVGATK) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus, tetramer is assembled by biotinylated monomer and streptavidin. It contains Gly25-Thr305 (HLA-A*03:01), Ile21-Met119 (B2M) and ALLAVGATK peptide (accession: NP_002107.3(HLA-A*03:01) & P61769(B2M) &ALLAVGATK).
Product Details
- Molecular Aliases
- gp100 (ALLAVGATK)
- Protein Length
- Gly25-Thr305
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reduced (N) condition based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human HLA-A*03:01&B2M&gp100 (ALLAVGATK) Tetramer on Bis-Tris PAGE under Non reduced (N) condition. The purity is greater than 95%.
The purity of Human HLA-A*03:01&B2M&gp100 (ALLAVGATK) Tetramer is greater than 95% as determined by SEC-HPLC.
Background
Immunization against the ALLAVGATK peptide may occur in melanoma patients and that the immunogenicity of this peptide is similar to that of the majority of melanoma differentiation antigens defined to date. Therefore, the use of ALLAVGATK in active immunotherapy for HLA-A3 melanoma patients, for whom no other immunogenic peptide has been so far described, remains a distinct possibility, providing that patients treated in vivo with this peptide develop a better in vitro response than already demonstrated for HLA-A2 epitopes generated from this same antigenic protein.
References
- Castelli C, Mazzocchi A, Rini F, Tarsini P, Rivoltini L, Maio M, Gallino G, Belli F, Parmiani G. Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1 melanoma patients. Eur J Immunol. 1998 Apr;28(4):1143-54. doi: 10.1002/(SICI)1521-4141(199804)28:04<1143::AID-IMMU1143>3.0.CO;2-K. PMID: 9565353.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.